Nov 10, 2022 / 02:00PM GMT
Göran Forsberg - Cantargia AB - CEO
Thank you so much. It's a pleasure to be here and present Cantargia's Q3 report. It's been an eventful and very interesting period, which we will go into more details on, and we will also explain a little bit where we are and where we are going.
So if we go to slide number 2, we have this information. And then with slide number 3, I would just say that besides myself, the presentation will also be given by Bengt Jöndell, our CFO.
So then moving into slide number 4, you can say that there has been a lot of things happening during this period. And most importantly, we performed a significantly oversubscribed rights issue during the summer and raised approximately SEK250 million before transaction costs. And this has really been important to make sure that we can progress with our key programs.
Besides that, there's also been scientific progress and especially in the preclinical and translational data in both our projects. So for nadunolimab, we made a very important publication around the antitumor efficacy in combination
Q3 2022 Cantargia AB Earnings Call Transcript
Nov 10, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers